Spyre Therapeutics, Inc. SYRE Research and development expense
Research and development expense at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s research and development expense?
- Spyre Therapeutics, Inc. (SYRE) reported research and development expense of $60.41M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s research and development expense changed year-over-year?
- Spyre Therapeutics, Inc.'s research and development expense increased by 45.1% year-over-year, from $41.62M to $60.41M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s research and development expense?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s research and development expense has grown at a 31.7% compound annual growth rate (CAGR), from $57.07M to $171.65M.